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Background: It is still not clear whether an intrapericardial pneumonectomy indicates a more advanced stage of
the disease compared to a standard pneumonectomy.
Methods: This was a retrospective study of 164 patients who underwent a pneumonectomy for lung cancer. The
first group consisted of 82 patients who had a standard pneumonectomy and the second group was 38 patients
who had a intrapericardial pneumonectomy, for both groups in the latest 5-year period. The third group was 44
patients with had a sleeve pneumonectomy in the latest 10-year period. The groups were compared in relation to
the overall and stage-related survival, influence of T and N factors, operative morbidity and mortality. The statistics
used were Kaplan–Meier, U-test, t-test, χ2 test.
Results: There was no statistically significant difference in stage distribution between standard and intrapericardial
pneumonectomies; stages I, II, IIIA and IIIB occurred for 10.9% vs 2.6%, 30.5% vs 26.3%, 46.4% vs 65.8% and 12.2% vs
5.3% of patients, respectively. For patients who had a sleeve pneumonectomy, stage IIIA was significantly more
frequent. Although the overall survival (63.5% vs 57.6%) and stage-related 5-year survival were better in the first
compared to the second group, especially for stage IIIA (58.6% vs 42.6%), these differences were not statistically
significant. There were no significant differences in operative morbidity and mortality between groups 1 and 2, but
both were significantly higher in the third group (35.7% and 15.9%).
Conclusions: An intrapericardial pneumonectomy does not always indicate a more advanced stage of the disease.
The need for an intrapericardial pneumonectomy, either established preoperatively or during the operation, as a
single factor, even for marginal surgical candidates, is not strong enough to reject these patients for surgery.Background
Despite a significant number of studies dealing with differ-
ent aspects of pneumonectomy, some of the conclusions
still remain unclear. The wide range for the reported
major complication rate of 17 to 47% is not fully counter-
balanced by the clearer situation for operative mortality,
where a broad consensus exists that a rate of 8% should
not be exceeded [1]. This is because standard and ex-
tended pneumonectomies are different operations and be-
cause intrapericardial pneumonectomy, without extension
to neighbouring structures, is rarely, if at all, addressed in
the literature.* Correspondence: profsubotic@gmail.com
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unless otherwise stated.An intrapericardial pneumonectomy may be necessary
either because of the invasion by the tumour of the extra-
pericardial part of the pulmonary artery and/or vein, or
due to the impossibility of safely dealing with the extraper-
icardial non-invaded part of the vessel as well. Finally,
pericardial involvement by the tumour also requires this
type of operation. Having in mind different reasons for the
opening and partial resection of the pericardium, we set
out to determine whether and in which way intrapericardial
pneumonectomies, without an extension of the resection to
adjacent structures, differ from standard pneumonectomies
and sleeve pneumonectomies, which are a variant of true
extended pneumonectomies.
An additional argument in favour of this study design is
the conflicting data on the outcome of pneumonectomies
in the era of neoadjuvant treatment. Usually with standard
and extended pneumonectomies analysed together, therel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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90-day mortality rate after right pneumonectomy in the
well-known report of Martini in 2001 [2], to 3.7% mortal-
ity in 27 patients undergoing pneumonectomy after induc-
tion therapy in a study by Perrot and colleagues [3].
Methods
This was a retrospective study of 164 patients who had a
pneumonectomy for primary lung cancer. The first group
consisted of 82 patients who had a standard pneumonec-
tomy, i.e. an extrapericardial pneumonectomy with sys-
tematic lymphadenectomy. The second group included 38
patients who had an intrapericardial pneumonectomy
without resection of adjacent structures. Patients in these
groups were operated on in the latest 5-year period. The
third group consisted of 44 patients who had a sleeve
pneumonectomy in the latest 10-year period.
In the present study, a standard pneumonectomy is
defined as a pneumonectomy without opening the peri-
cardium, with a routinely performed systematic lymph-
adenectomy. The term intrapericardial pneumonectomy
in this study relates to a pneumonectomy without resec-
tion of the chest wall, left atrium, vena cava, tracheal bi-
furcation or oesophagus, but with opening of the
pericardium (with or without its partial excision), be-
cause of the direct invasion of the tumour into the
extrapericardial part of the pulmonary artery and/or
vein (with or without pericardial involvement). A sleeve
pneumonectomy refers only to a full-circumference anas-
tomosis between the trachea and right or left (three pa-
tients) main bronchus.
Inclusion criteria
Patients were included if they had undergone a complete
resection (R0) and there was precise data about the pre-
treatment tumour and patient characteristics and comor-
bidities; a detailed post-surgery pathohistological report;
and precise data about postoperative complications, neo-
adjuvant or adjuvant therapy and treatment outcome.
Preoperative work up
The preoperative work up for the assessment of the local
extent of the lung cancer was the same in all groups
(standard clinical and laboratory investigations, bronchos-
copy, high-resolution computed tomography scan of the
thorax and upper abdomen and respiratory function tests).
For the staging of the mediastinum, a positron emission
tomography (PET) scan was performed only for patients
with a shorter lymph node diameter >1.5 cm. A mediasti-
noscopy was performed only for PET-positive patients.
For patients with moderate and severe chronic obstruct-
ive pulmonary disease (COPD), according to the GOLD
criteria, we calculated the predicted postoperative forced
expiratory volume in 1 second (ppoFEV1) using a perfusionlung scintigraphy with quantification of perfusion for each
lung. A value of ppoFEV1 > 30% is accepted as a lower limit
for safe lung resection. For all patients with cardiac comor-
bidity, a peak oxygen consumption of 15 ml.kg-1.min-1
served as a cut-off value for safe resection, according to
current guidelines. The tumours were classified and staged
according to the 2009 revision of the International System
for Staging of Lung Cancer.
For all patients, bronchial closure was performed with
a running suture (using polydioxanone (PDS) 2–0 cartil-
age to cartilage, membranous to membranous) with two
or three reinforcing interrupted stitches (PDS 3–0). For
patients undergoing a right pneumonectomy after neo-
adjuvant treatment, the bronchial suture line was almost
routinely protected by the intercostal muscle flap, peri-
cardial fat pad or diaphragm muscle flap.
Data analysis
The demographic and clinical data were collected from
the patients' original dossiers and at the time of outpatient
visits, or by contacting the patients, their relatives or phy-
sicians by phone. All the data obtained were entered into
the database. The groups were compared in relation to the
overall and stage-related survival, influence of T and N
factors, neoadjuvant treatment, operative morbidity and
mortality. Survival time was calculated from the date of
operation.
Statistics
Survival was calculated using the Kaplan–Meier method.
The log-rank test was used to compare survival between
the groups; P < 0.05 was considered to indicate a statisti-
cally significant result. All statistical analyses were per-
formed using SPSS software (version 13.0 for Windows).
A multivariate analysis was used to evaluate the effect of
different covariates on the treatment outcome and com-
plication rate. Other statistical tests used were the U-test
to analyse disease stage distribution throughout the ana-
lysed groups; the t test to compare ventilatory parame-
ters and the χ2 test for an intergroup comparison of
operative morbidity, mortality and bronchopleural fistula
occurrence. The study was approved by the institutional
review board of the Clinic for thoracic surgery of the
Clinical center of Serbia in Belgrade.Results
Group structure, baseline lung function and disease
stage distribution
The structure of the analysed groups is presented in
Table 1. There were no significant differences in the age
of the patients; the mean ages for the standard, intraper-
icardial and sleeve pneumonectomy groups were 58.9 ±
7.8, 58.7 ± 6.2 and 51.4 ± 5.7 years, respectively.
Table 1 Structure of the analysed groups
Group 1 Group 2 Group 3 P
Age (mean ± standard deviation) (years) 58.9 ± 7.8 58.7 ± 6.2 51.4 ± 5.7 <0.05
Side (right/left) 38/44 22/16 41/3 G1:G2: P > 0.05
G1 + G2 vs G3: P < 0.05
n (%) n (%) n (%)
Operative stage Ia 2 (2.4) 1 (2.6) 0 (0) >0.05
Ib 7 (8.5) 0 (0) 0 (0)
IIa 17 (20.7) 3 (7.9) 0 (0)
IIb 8 (9.8) 7 (18.4) 0 (0)
IIIa 38 (46.4) 25 (65.8) 26 (59)
IIIb 10 (12.2) 2 (5.3) 18 (41)
COPD Mild 10 (12.2) 4 (10.5) 5 (11.3) COPD total
Moderate 9 (10.9) 4 (10.5) 9 (20.5) G1: G2:G3
Severe 0 (0) 0 (0) 1 (2.2) P = 0.196
COPD total 19 (23.1) 8 (21) 15 (34)
Cardiovascular risk 10 (12.2) 5 (13.2) 6 (13.6) >0.05
Other comorbidities* 10 (12.2) 5 (13.2) 5 (11.4) >0.05
Neoadjuvant therapy 22 (26.8) 12 (31.6) 5 (11.4) G1:G2: P > 0.05
G1 + G2 vs G3: P < 0.05
Adjuvant therapy 30 (36.5) 15 (39.4) 19 (43.2) >0.05
Tumour histology Squamous 55 (67) 26 (68.4) 35 (79.6) >0.05
Adeno Ca 24 (29.2) 10 (26.3) 5 (11.4)
Other 3 (3.6) 2 (5.3) 4 (9.1)
T component T1 9 (10.9) 4 (10.5) 0 (0) G1 + G2 vs G3
T2 37 (45.1) 10 (26.3) 0 (0) <0.05
T3 21 (25.6) 19 (50) 16 (36.4)
T4 15 (18.3) 5 (13.2) 18 (32.14)
N2 lesions 25 (30.5) 12 (31.6) 22 (50) <0.05
G1, group 1; G2, group 2; G3, group 3.
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pneumonectomy, the proportion of right- vs left-sided
tumours was 38 vs 44 and 22 vs 16, respectively. For pa-
tients who had a sleeve pneumonectomy, the right-sided
operation was performed for 41 patients, whilst for 3 pa-
tients a one-stage left sleeve pneumonectomy was done.
The preoperative lung function was well preserved in all
groups. There was no significant difference in the baseline
lung function parameters between the analysed groups. In
the standard pneumonectomy group, COPD was diagnosed
for 19 (23.17%) patients. In the intrapericardial pneumon-
ectomy and sleeve pneumonectomy group, there were 8
(21%) and 15 (34%) patients with COPD, respectively.
Despite a clearly higher proportion of postoperative
stages IIB and IIIA in the intrapericardial group vs standard
pneumonectomy group, there was no statistically significant
difference in stage distribution between the first and second
groups (standard vs intrapericardial pneumonectomy),where stages I, II, IIIA and IIIB were for 10.9% vs 2.6%,
30.5% vs 26.3%, 46.4% vs 65.8% and 12.2% vs 5.3%
respectively.
Ten patients who had a standard pneumonectomy
were classified as stage IIIB based on the involvement of
the oesophageal muscular layer (two patients), N3 le-
sions (one patient), additional lung nodules in the non-
primary tumour lobes (three patients), direct phrenic
nerve involvement (two patients) and mediastinal fat
pad involvement (two patients). For patients who had a
sleeve pneumonectomy, stage IIIA was for 26 patients
(59%) and stage IIIB for 18 patients (41%).
Comorbidity, adjuvant/neoadjuvant treatment, operative
morbidity and mortality
For the preoperative comorbidities, for patients who had a
standard or intrapericardial pneumonectomy, COPD was
diagnosed for 19 (23.17%) and 8 (21%) patients, respectively.
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(12.2%) and 5 (13.2%) patients, respectively. These differ-
ences were not statistically significant.
In the sleeve-pneumonectomy group, major cardiovas-
cular risk factors were identified in 6 patients (13.6%)
(two of whom died in the early postoperative period),
whilst COPD was found in 15 patients (34%). The evi-
dently higher proportion of COPD patients in the latter
group, compared with the first two groups, was not sig-
nificantly significant.
Other comorbidities, like diabetes, gastric ulcer, previ-
ous CVI and chronic renal failure, were found for the
first, second and third groups for 10 (12.2%), 5 (13.2%)
and 5 (11.365%) patients, respectively. There were no
significant differences between the analysed groups for
these comorbidities.
In the standard pneumonectomy group, postoperative
complications occurred in 7/39 (17.95%) patients with
a comorbidity and in 4/43 (9.35) patients without a
comorbidity. In the intrapericardial pneumonectomy
group, postoperative complications in patients with and
without a comorbidity were registered in 4/18 (22.2%)
and 3/20 (15%) patients, respectively. Although the
postoperative complications were more frequent in pa-
tients with a comorbidity, these differences were not
statistically significant, neither in these two, nor in the
sleeve pneumonectomy group.
Postoperative complications occurred more frequently
in patients with COPD (22%) and cardiovascular diseases
(20%) compared to other types of comorbidity (13.3%),
but these differences were not statistically significant.
Preoperative chemotherapy was administered to 22
patients (26.8%) who had a standard pneumonectomy,
to 12 patients (31.5%) who had an intrapericardial pneu-
monectomy and to 5 (11.3%) patients who had a sleeve
pneumonectomy.
In the first and second groups, postoperative adjuvant
chemo/radiation therapy was administered to 30 (36.5%)
and 15 (39.4%) patients, respectively. In the sleeve pneu-
monectomy group, postoperative adjuvant treatment was
given to 19 patients (43.2%). Seven patients received chemo-
therapy and 12 were irradiated postoperatively. For only one
patient, who was irradiated postoperatively, pleural empy-
ema without a bronchopleural fistula occurred.
In the first, second and third groups, postoperative
complications within 30 postoperative days occurred in
11/82 (13.4%), 7/38 (18.4%) and 15/44 (34%) respect-
ively (Table 2). Operative morbidity was significantly
higher in the sleeve pneumonectomy compared with
other two groups. Although bronchopleural fistulas oc-
curred more frequently in the sleeve pneumonectomy
group (6/44, 13.6%) compared to the first (5, 6.09%) and
second (1, 2.6%) groups, these differences were not sta-
tistically significant.In the sleeve-pneumonectomy group, the postoperative
complications were: bronchopleural fistula (six patients),
pulmonary embolism (one), myocardial infarction (one),
gastric stress ulcer (one), pleural empyema (two) and car-
diac arrhythmias (four).
Among several analysed factors, only age and postopera-
tive T factor were found to be significantly unfavourable in
terms of the bronchopleural fistula occurrence for the first
and second groups (Table 3). Age, sex, tumour side, pre-
operative lung function, neoadjuvant treatment and post-
operative N factor were not confirmed as significant
contributive factors. In the sleeve-pneumonectomy group,
T (hazard ratio 2.37, P < 0.04) and N component (hazard
ratio 2.99, P < 0.01) were found to be significant.
In the first two groups, no patients died within the first
30 postoperative days. In the sleeve-pneumonectomy
group, operative mortality was 7/44 (15.95%). Of the seven
patients who died, four had a bronchopleural fistula,
whilst a pulmonary embolism, myocardial infarction and
gastric ulcer occurred in one patient each.
Survival
The survival of patients in the analysed groups is pre-
sented in Figure 1. The 5-year survival of patients who
had a standard, intrapericardial or sleeve pneumonectomy
was 63.5%, 57.6% and 35%, respectively. The mean survival
of patients who had a standard or intrapericardial pneu-
monectomy was 59.6 ± 4.5 and 51.3 ± 6.2 months, respect-
ively. Despite evident survival differences for stage IIIA
patients (Figure 2), there was no significant difference in
stage-related survival between groups 1 and 2 (Table 4). Sur-
vival depending on nodal stage in patients who had a stand-
ard or intrapericardial pneumonectomy is presented in
Figures 3 and 4, respectively. For patients who had a sleeve
pneumonectomy, there was a significant survival difference
between patients with N0 +N1 vs N2 lesions (Figure 5).
The tumour side did not significantly influence survival
in the analysed groups (Table 5). There were only three
left-sided operations in the sleeve-pneumonectomy group
(one patient died on postoperative day 5 from a massive
pulmonary embolism, another survived one year), which
does not allow reliable conclusions to be reached.
Discussion
Stage distribution
In the present study, the term standard pneumonectomy
refers only to pneumonectomy with systematic lymphade-
nectomy, but without opening the pericardium and without
resection of other structures. In some studies, however,
standard pneumonectomy was defined in the same way,
but including both intrapericardial and extrapericardial
lung removal [4]. The reason for our definition was that for
the study end point we aimed to assess eventual differences
between the two types of operation.
Table 2 Postoperative morbidity, mortality and bronchopleural fistula occurrence
Group 1 Group 2 Group 3 χ2 P
n (%) n (%) n (%)
Postoperative morbidity 11/82 (13.4) 7/38 (18.4) 15/44 (34) 7,705 0.021
Postoperative mortality 0 (0) 0 (0) 7/44 (15.9) * **
Bronchopleural fistula 5/82 (6.1) 1/38 (2.6) 6/44 (13.6) 4,001 0.135
*Group 1 vs group 3 (χ 2 = 10.947); group 2 vs group 3 (χ 2 = 4.729).
**Group 1 vs group 3 (P = 0.029); group 2 vs group 3 (P < 0.001).
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monectomies at early disease stages may be quite high,
reaching nearly 30% in some series, like in a recent multi-
centre review of 1,475 patients with pathologic stage I or
II NSCLC, where 421 (28.5%) patients underwent a pneu-
monectomy and 1,054 (71.5%) underwent a lobectomy or
bilobectomy [5]. Moreover, after adjusting for age, primary
tumour status, regional nodal status and preoperative
FEV1, it was also shown that survival after pneumonec-
tomy may not differ significantly compared with lobec-
tomy/bilobectomy [6].
Concerning the stage distribution, an adequate com-
parison is possible with the small number of studies spe-
cifically addressing an intrapericardial operation as a
single factor, like in a series of 130 intrapericardial pneu-
monectomies [7]. Our finding of the absence of signifi-
cant differences for the stage distribution between the
standard and intrapericardial pneumonectomy groups is
caused by the relatively high proportion of lower disease
stages in the intrapericardial group – 26.3%, which is
similar to the aforementioned study with 30/130 (23%)
patients in stage II. The relatively high proportion of T2
tumours in that study – 70/130 (53.8%), 2 with N0, 28
with N1 and 40 with N2 – confirms that the decision for
the opening of the pericardium does not always reflect a
more advanced local spread, but also tumour location.
In addition, the proportion of stage IIIA patients in that
study 86/130 (66%) was somewhere in between the pro-
portion of that stage in our standard (58.5%) and intra-
pericardial pneumonectomy groups (71.1%).
In brief, a pneumonectomy in early disease stages may
have two opposed effects: an unfavourable effect (especiallyTable 3 Factors influencing the occurrence of a bronchopleur
Factors B SE Df Sig
Sex −0.795 0.857 1 0.3
Age 0.135 0.061 1 0.0
FEV1 (%) 0.018 0.026 1 0.4
Tumour side 0.014 0.597 1 0.9
pT* 1.390 0.424 1 0.0
pN** 0.796 0.576 1 0.1
Neoadjuvant −0.579 0.800 1 0.4
*Significant in all groups.
**Significant only for the third group (hazard ratio 2.99, P < 0.01).for a right pneumonectomy) on cardiorespiratory function
and a more favourable one through the reduced risk of
local relapse, possibly due to a better clearance of N1 lymph
nodes, as suggested by Luzzi and colleagues [8].
Operative morbidity and mortality
The almost identical major cardiovascular comorbidity
rate (12% to 13%) and similar proportion of COPD pa-
tients in the present study, minimized the possible influ-
ence of comorbidity on operative morbidity and mortality.
The absence of 30-day mortality and similar morbidity
rates (13.4% and 18.45%) in the first two groups of the
present study are on the lower end of the reported 12% to
37% complication rate, even without neoadjuvant therapy.
The rare reports of mortality and morbidity exclusively
after intrapericardial pneumonectomy have rates ranging
from 5% to 10% and reaching 20% [9,10].
The significantly higher morbidity (34%) and mortality
(16%) rates in the sleeve-pneumonectomy group, mir-
rored the experience of Tsuchiya and Watanabe, who re-
ported an operative mortality of 15% to 17% as an
acceptable risk [11]. In the sleeve-pneumonectomy group,
the cardiovascular complication rate was slightly lower
than the rate reported in the literature, and is the same as
for standard pneumonectomy [12].
One of the possible causes of the high mortality and
morbidity rate in the sleeve-pneumonectomy group could
be the unexpected sleeve resection. In the present study, a
sleeve resection was not expected before the operation for
11 patients (25%). Except for the study of Porhanov et al.
[13], which is the world’s largest experience of sleeve
pneumonectomy with 189 patients operated on, otheral fistula








Figure 1 Overall survival. 1: Standard pneumonectomy. 2: Intrapericardial pneumonectomy. 3: Sleeve pneumonectomy.
Figure 2 Survival for stage IIIA patients (groups 1 and 2). 1: Standard pneumonectomy. 2: Intrapericardial pneumonectomy.
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Table 4 Significance of stage-related survival for groups 1 and 2
Operative stage Standard (group 1) Intrapericardial (group 2) DF Sig.
Mean Standard deviation Mean Standard deviation Mean Standard deviation
IIB 74.5 10.7 54.2 8.3 1 0.273
IIIA 54.0 7.1 38.3 7.2 1 0.399
IIIB 18.1 4.1 72.5 0 1 0.123
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cessity for a sleeve pneumonectomy was revealed during
the operation for 23% of patients, but the causes were not
analysed. In our group, all such patients had either a
tumour in the main bronchus or in the upper lobe, but al-
ways with invasion of the main carina from outside the
bronchial wall.
The reason for focusing on factors influencing the oc-
currence of a bronchopleural fistula in the present study,
was our observation that cardiac disorders or respiratory
insufficiency, usually reported as separate complications,
may be direct consequences or even the first sign of a
bronchopleural fistula. We can only speculate that the
quite low bronchopleural fistula rate in the present study
(6.09% and 2.6% for standard and intrapericardial pneu-
monectomies) can be explained by our technique of man-
ual closure of the bronchus (as described); this technique
was used for all patients.
In contrast to the literature data, which shows that a
right-sided pneumonectomy is associated with a mortal-
ity of 12% to 37% even in the absence of neoadjuvantFigure 3 Survival depending on nodal stage for patients who had a schemoradiation therapy, in the present study the
tumour side was not significant in terms of the occur-
rence of a bronchopleural fistula. Although this finding
is similar to those of the small number of studies that
have found no significant influence for the tumour side
[14,15], these studies were smaller, with data collected
over many years. In studies with a high reported operative
mortality (20% 90-day mortality after right-sided vs 9%
after left-sided pneumonectomy, P = 0.084), there was a
high rate (12%) of bronchopleural fistula as well [16]. Fur-
thermore, in some studies the significant difference in
major operative morbidity depending on tumour side
(with a right vs left respiratory failure rate of 37% vs 8%),
was associated with significant survival differences in
favour of left-sided tumours [4].
Unlike the tumour side, patients’ age was found to be sig-
nificant in terms of the occurrence of a bronchopleural fis-
tula, which is in line with most literature data, as only a few
studies support the lack of an association between advanced
age and morbidity [17]. There is still some controversy re-
lated to the age limit for a safe resection. According totandard pneumonectomy.
Figure 4 Survival depending on nodal stage for patients who had a intrapericardial pneumonectomy.
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increase in the rate of major complications. The American
College of Cardiology and American Heart Association
(ACC/AHA) practice guideline indicates that patients of
70 years or older carry a particularly high risk for peri-
operative cardiac morbidity [18]. The median age of our
study population of 59 years is similar to that reported in
publications on patients undergoing a pneumonectomy
for lung cancer, which is 58 to 65 years [19]. As the num-
ber of patients older than 65 years undergoing thoracic
surgery is estimated to increase from the current 6 million
to nearly 12 million per year, we do not limit surgery toFigure 5 Survival depending on nodal stage for patients who had a sthe proven low-risk age group; in the present study, 8 pa-
tients were older than 70 years in the first group and one
in the second group.
The absence of the significant influence of FEV1 on op-
erative morbidity is probably a consequence of the quite
low number of COPD patients – 23.17% in the first and
21% in the second group. We also avoided sacrificing the
phrenic nerve whenever possible during the intrapericar-
dial pneumonectomies, by mobilising and retracting it
medially. This is because it has been clearly demonstrated
that preserving the phrenic nerve may be beneficial in
terms of postoperative lung function [20]. Although aleeve pneumonectomy.
Table 5 Survival in groups 1 and 2 depending on tumour side
Procedure Tumour side Mean Standard error Lower Upper Chi squared Df Sig.
Standard pneumonectomy Right 57.82 6.45 44.63 69.93
Left 55.08 4.94 45.40 64.76 0.106 1 0.745
Intrapericardial pneumonectomy Right 55.60 8.11 39.69 71.50
Left 51.28 6.23 39.06 63.49 0.667 1 0.414
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sleeve-pneumonectomy group coincided with a quite high
(36.36%) proportion of COPD patients, this complication
cannot be attributed to COPD, as for the 4/6 patients who
died with a bronchopleural fistula, the length of the
resected tracheo-bronchial segment was >4 cm. The litera-
ture data are conflicting: only a few studies have found
FEV1 to contribute as a predictor of morbidity or mortality
in multivariate analysis [21] and also a number of studies
have not confirmed such an association [15,16]. That is
why in the present study, like in our previous experience
with COPD patients, beside the FEV1, we included in the
analysis the small airways function (FEF50, FEF25) as well.
Although we previously demonstrated that this part of the
lung function may be significantly improved preopera-
tively [22], no significant influence on operative morbidity
was demonstrated in the present study.
Due to the retrospective nature of the study, in the ana-
lysis of the influence of neoadjuvant treatment (mostly
chemotherapy), the inconsistent policy for N2 lesions
should be kept in mind. This relates more to the first two
groups, in which 26.8% and 31.5% patients received neo-
adjuvant treatment, than for the sleeve-pneumonectomy
group with 11.3% such patients. Our results support the
results of studies that have recently challenged the trad-
itionally reported high complication rate after this type of
treatment; there was 3.7% mortality in the study by Perrot
and colleagues [3] and 6.7% mortality after neoadjuvant vs
5.5% for 238 patients undergoing surgical treatment alone
in the series described by Mansour and colleagues [23].
That there were no deaths within the first 30 postoperative
days in the first two groups of the present study, may be
attributed to the absence of preoperative irradiation ther-
apy for these groups. In addition, for right-sided pneu-
monectomies, the bronchial suture line was almost
routinely protected as previously described.
Survival
The slightly superior survival rates in the first two ana-
lysed groups (63.55% and 57.6%) compared with those
reported in many other series, was due to the higher
proportion of lower disease stages in both groups and to
the shorter follow-up of patients operated later in the
latest 5-year period. On the other hand, the reported
survival after neoadjuvant treatment (33 to 46%) for pa-
tients with a regionally advanced disease [24], confirmsthat the long-term results after pneumonectomy, even
for these unfavourable groups, may be acceptable. How-
ever, one of the main study end points was the compari-
son of survival between the first and second groups. The
absence of a significant difference in stage-related sur-
vival between groups 1 and 2, despite evident survival
differences for stage IIIA patients, strongly supports our
initial clinical observations that extension of the resec-
tion into the pericardium does not necessarily mean a
worse outcome.
Survival after sleeve pneumonectomy reflects the
major differences between the groups from the stand-
point of patient selection, operative risk and final out-
come. The 5-year survival of patients in our group is
better than that found by several studies with 16 to 40
patients, but is still lower than the 43% survival rate re-
ported by Dartevelle and Macchiarini [25]. The signifi-
cant survival difference in favour of patients without
pN2 lesions vs patients with pN2 lesions in our series
clearly supports the attitude that this operation should
not be performed for patients with N2 lesions that are
confirmed either before or during thoracotomy. The lit-
erature data are heterogeneous regarding the signifi-
cance of nodal stage; attitudes vary from not accepting
suspected N2 lesions as a contraindication to surgery,
through performing mediastinoscopy only in the pres-
ence of tracheal compression above the anticipated line
of resection, to routine mediastinoscopy for all candi-
dates for this operation [26].
Study limitations
A comparison of patients who have had a standard,
intrapericardial or sleeve pneumonectomy as separate
groups might seem debatable. However, in the Methods
section, the explanation for this approach was given and
was subsequently confirmed by the results, which show
that standard and intrapericardial pneumonectomies
(without extension to surrounding structures) are not
necessarily associated with more extensive disease
spread, regardless of whether the pericardium was only
opened or partially resected. An intrapericardial pneu-
monectomy is by no means more similar to a sleeve
pneumonectomy than to a standard pneumonectomy. A
sleeve pneumonectomy is a variant of an extended pneu-
monectomy and, as such, completely different from the
other two operations.
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To conclude, the operative risk and outcome after an
intrapericardial pneumonectomy, without resection of sur-
rounding structures, are comparable to those after a
standard pneumonectomy. If the need for an intrapericar-
dial pneumonectomy is determined either preoperatively or
during the operation, this fact, even for marginal surgical
candidates, is not strong enough to reject these patients
for surgery.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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